Filana Therapeutics to Participate in the 2026 Maxim Growth SummitGlobeNewsWire · Oct 9, 2026
Positive FDA Decision Propels Rebranded Filana Therapeutics Epilepsy Research ForwardBenzinga · Sep 22, 2026
Filana Therapeutics Announces FDA Lift of Clinical Hold on Simufilam, Enabling Phase 2a Study in TSC-Related EpilepsyGlobeNewsWire · Sep 22, 2026
Did Filana Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?GuruFocus · Aug 12, 2026
Did Filana Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?PRNewsWire · Aug 12, 2026
Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business UpdateGlobeNewsWire · Jul 29, 2026Filana Therapeutics, Inc. is a company dedicated to pioneering new pharmaceutical products and diagnostic technologies. A key area of its research is focused on creating potential treatments for Alzheimer's disease, including the investigational compounds PTI-125 and PTI-125Dx. Established by Remi Barbier in May 1998, the firm maintains its principal office in Austin, Texas.
| Date | Est. | Actual | |
|---|---|---|---|
| Jul 29, 2026 | -$0.23 | -$0.18 | Beat |
| May 7, 2026 | -$0.23 | -$0.21 | Beat |
| Mar 12, 2026 | -$0.30 | -$0.26 | Beat |
| Nov 12, 2025 | -$0.27 | -$0.22 | Beat |
| Aug 14, 2025 | – | -$0.92 | |
| May 8, 2025 | – | -$0.48 |